4'-bromo-2-trifluoromethyl-biphenyl-4-amine | 853299-23-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-bromo-2-trifluoromethyl-biphenyl-4-amine
• 英文别名: 4-(4-bromophenyl)-3-(trifluoromethyl)aniline
• CAS: 853299-23-7
• 化学式: C₁₃H₉BrF₃N
• 分子量: 316.12
• InChiKey: KDEOQVWQDMGPHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3'-chloro-2-trifluoromethyl-biphenyl-4-yl)-3-{4-[2-(4-dimethylamino-butylamino)-pyrimidin-4-yloxy]-2-methyl-phenyl}-urea 、 4'-bromo-2-trifluoromethyl-biphenyl-4-amine 在 1-(4'-Bromo-2-trifluoromethyl-biphenyl-yl)-3-{4-[2-(4-dimethylamino-butylamino)-pyrimidin-4-yloxy]-2-methyl-phenyl}urea 作用下， 以 methanol-dichloromethane 为溶剂， 生成 1-(4'-Bromo-2-trifluoromethyl-biphenyl-yl)-3-{4-[2-(4-dimethylamino-butylamino)-pyrimidin-4-yloxy]-2-methyl-phenyl}urea
  参考文献：
  名称：

  Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases

  摘要：

  本发明涉及利用二芳基脲衍生物制造药物组合物，用于治疗RET依赖性疾病，特别是RET依赖性肿瘤疾病。本发明还涉及新的N-[4-(嘧啶-4-氧基)-苯基]-N'-苯基脲衍生物及其在动物或人体内治疗蛋白激酶依赖性疾病，特别是增殖性疾病，如肿瘤疾病方面的用途。此外，本发明还涉及包含这种新的N-[4-(嘧啶-4-氧基)-苯基]-N'-苯基脲衍生物的药物组合物，以及利用这种新的N-[4-(嘧啶-4-氧基)-苯基]-N'-苯基脲衍生物制备用于治疗蛋白激酶依赖性疾病，特别是增殖性疾病，如肿瘤疾病的药物组合物的用途。

  公开号：

  US20080312192A1

文献信息

• DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES
  申请人：Novartis AG

  公开号：EP1689376A2

  公开（公告）日：2006-08-16
• [EN] DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES<br/>[FR] DERIVES DE DIARYLUREE UTILISES EN TRAITEMENT DE MALADIES DEPENDANT DE PROTEINES KINASES
  申请人：NOVARTIS AG

  公开号：WO2005051366A2

  公开（公告）日：2005-06-09

  The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.